Bio Life Solutions CEO Mike Rice said the company’s new corporate facilities and expanded operations and support areas will enable it to increase production of platform HypoThermosol and CryoStor biopreservation media products, and also to stage and store raw materials and finished biopreservation media products manufactured under contract.
”Our second, independent, multi-classed cGMP clean room suite is currently in the validation phase and we look forward to bringing this on line early in the fourth quarter of 2012," Rice added.
"Our investments in additional manufacturing capacity and new team members will enable us to meet current and future demand for our proprietary products, as we are optimistic that some number of our customers in the regenerative medicine market will gain marketing and regulatory approval for their cell and tissue-based products, which incorporate HypoThermosol and/or CryoStor as critical storage, shipping, freezing, and infusion reagents.”
Biolife Solutions develops, manufactures and markets patented hypothermic storage and cryopreservation freeze media products for cells and tissues.